secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anebulo Pharmaceuticals, Inc. (ANEB)
CIK:        0001815974
Form:       8-K
Filed at:   2023-03-08T23:59:59+00:00
Accession:  0001493152-23-006974
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anebulo appoints Sandra A. Gardiner as Acting CFO via Potrero Hill Advisors agreement
--------------------------------------------------------------------------------

- Sandra A. Gardiner appointed Acting CFO, principal financial and accounting officer effective March 2, 2023.
- Gardiner replaces Rex Merchant; she will provide services through Master Services Agreement with Potrero Hill Advisors.
- Gardiner previously served as CFO of Pulse Biosciences (Nasdaq: PLSE) and Cutera, Inc.
- Master Services Agreement has five-year term, hourly rate compensation with annual 5% increase option, and 30-day termination notice.
- No direct agreement between Company and Gardiner; all terms governed by the consulting arrangement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815974/000149315223006974/0001493152-23-006974-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815974/000149315223006974/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-006974

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer